You are here
Our Partners
Angiochem has and will continue to form strategic alliances with companies and organizations to further apply its EPiC platform technology, advance development of its EPiC drug candidates and access complementary research, technology and development capabilities.
Collaboration with Geron Corporation
Angiochem and Geron have established a collaboration including a global and exclusive license to Angiochem’s proprietary peptide EPiC technology for two oncology product categories (taxanes and telomerase inhibitors). Under the terms of the collaboration, Geron has acquired exclusive global product rights to GRN1005, a novel targeted taxane derivative which is Angiochem’s most advanced product candidate derived from the EPiC platform.
Read more >